• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双吲哚衍生的 NR4A1 拮抗剂抑制结肠肿瘤和脾脏生长以及 T 细胞耗竭。

Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.

机构信息

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA.

Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, 77843, USA.

出版信息

Cancer Immunol Immunother. 2023 Dec;72(12):3985-3999. doi: 10.1007/s00262-023-03530-3. Epub 2023 Oct 17.

DOI:10.1007/s00262-023-03530-3
PMID:37847301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10700478/
Abstract

There is evidence that the orphan nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in exhausted CD8 + T cells and regulates PD-L1 in tumors. This study investigated the effects of potent bis-indole-derived NR4A1 antagonists on reversing T-cell exhaustion and downregulating PD-L1 in colon tumors/cells. NR4A1 antagonists inhibited colon tumor growth and downregulated expression of PD-L1 in mouse colon MC-38-derived tumors and cells. TILs from MC-38 cell-derived colon tumors and splenic lymphocytes exhibited high levels of the T-cell exhaustion markers including PD-1, 2B4, TIM3+ and TIGIT and similar results were observed in the spleen, and these were inhibited by NR4A1 antagonists. In addition, treatment with NR4A1 antagonists induced cytokine activation markers interferon γ, granzyme B and perforin mRNAs and decreased TOX, TOX2 and NFAT in TIL-derived CD8 + T cells. Thus, NR4A1 antagonists decrease NR4A1-dependent pro-oncogenic activity and PD-L1 expression in colon tumors and inhibit NR4A1-dependent T-cell exhaustion in TILs and spleen and represent a novel class of mechanism-based drugs that enhance immune surveillance in tumors.

摘要

有证据表明,孤儿核受体 4A1(NR4A1,Nur77)在耗尽的 CD8+T 细胞中过度表达,并调节肿瘤中的 PD-L1。本研究探讨了强效双吲哚衍生的 NR4A1 拮抗剂对逆转 T 细胞耗竭和下调结肠肿瘤/细胞中 PD-L1 的影响。NR4A1 拮抗剂抑制了源自小鼠结肠 MC-38 的肿瘤和细胞中结肠肿瘤的生长,并下调了 PD-L1 的表达。源自 MC-38 细胞的结肠肿瘤和脾淋巴细胞中的 TIL 表现出高水平的 T 细胞耗竭标志物,包括 PD-1、2B4、TIM3+和 TIGIT,并且在脾脏中观察到类似的结果,这些结果可被 NR4A1 拮抗剂抑制。此外,NR4A1 拮抗剂处理诱导细胞因子激活标志物干扰素 γ、颗粒酶 B 和穿孔素 mRNAs 的表达,并降低 TIL 衍生的 CD8+T 细胞中的 TOX、TOX2 和 NFAT。因此,NR4A1 拮抗剂降低了 NR4A1 依赖性致癌活性和结肠肿瘤中的 PD-L1 表达,并抑制了 TIL 和脾脏中 NR4A1 依赖性 T 细胞耗竭,代表了一类增强肿瘤免疫监视的新型机制药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/fe24735746e5/262_2023_3530_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/8db6045b326f/262_2023_3530_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/ef9094a6f1b9/262_2023_3530_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/bb004c4c6fc8/262_2023_3530_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/943955f6a8e3/262_2023_3530_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/3111ff100d7d/262_2023_3530_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/8bea1e2391ea/262_2023_3530_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/fe24735746e5/262_2023_3530_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/8db6045b326f/262_2023_3530_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/ef9094a6f1b9/262_2023_3530_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/bb004c4c6fc8/262_2023_3530_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/943955f6a8e3/262_2023_3530_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/3111ff100d7d/262_2023_3530_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/8bea1e2391ea/262_2023_3530_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/babc/10992034/fe24735746e5/262_2023_3530_Fig7_HTML.jpg

相似文献

1
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.双吲哚衍生的 NR4A1 拮抗剂抑制结肠肿瘤和脾脏生长以及 T 细胞耗竭。
Cancer Immunol Immunother. 2023 Dec;72(12):3985-3999. doi: 10.1007/s00262-023-03530-3. Epub 2023 Oct 17.
2
A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.一种双吲哚衍生的 NR4A1 拮抗剂诱导 PD-L1 降解并增强抗肿瘤免疫。
Cancer Res. 2020 Mar 1;80(5):1011-1023. doi: 10.1158/0008-5472.CAN-19-2314. Epub 2020 Jan 7.
3
Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.核受体 4A1(NR4A1)拮抗剂诱导子宫内膜癌细胞中 ROS 依赖的 mTOR 信号抑制。
Gynecol Oncol. 2019 Jul;154(1):218-227. doi: 10.1016/j.ygyno.2019.04.678. Epub 2019 Apr 30.
4
Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis.双吲哚衍生核受体 4A1(NR4A1,Nur77)配体作为子宫内膜异位症的抑制剂。
Endocrinology. 2020 Apr 1;161(4). doi: 10.1210/endocr/bqaa027.
5
Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.双吲哚衍生核受体 4A1(NR4A1)拮抗剂强烈抑制乳腺癌。
Breast Cancer Res Treat. 2019 Aug;177(1):29-40. doi: 10.1007/s10549-019-05279-9. Epub 2019 May 22.
6
TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 T cell exhaustion.TOX 和 TOX2 转录因子与 NR4A 转录因子合作,对 CD8 T 细胞衰竭施加影响。
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415. doi: 10.1073/pnas.1905675116. Epub 2019 May 31.
7
The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.核孤儿受体NR4A1调节胰腺癌细胞和结肠癌细胞中的β1整合素表达,并且可被NR4A1拮抗剂靶向作用。
Mol Carcinog. 2017 Sep;56(9):2066-2075. doi: 10.1002/mc.22662. Epub 2017 May 9.
8
Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.核受体4A1作为乳腺癌化疗的药物靶点。
Endocr Relat Cancer. 2015 Oct;22(5):831-40. doi: 10.1530/ERC-15-0063. Epub 2015 Jul 30.
9
Presence of Tim3 and PD-1 CD8 T cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features.Tim3 和 PD-1 共表达的 CD8 T 细胞可鉴定出具有免疫衰竭和独特临床病理特征的微卫星稳定型结直肠癌。
J Pathol. 2022 Jun;257(2):186-197. doi: 10.1002/path.5877. Epub 2022 Apr 9.
10
Deletion of Cbl-b inhibits CD8 T-cell exhaustion and promotes CAR T-cell function.Cbl-b 的缺失抑制了 CD8 T 细胞衰竭并增强了 CAR T 细胞的功能。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001688.

引用本文的文献

1
Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance.解读腺苷脱氨酶作用于RNA(ADARs)在癌症发病机制、肿瘤免疫逃逸和耐药性中的机制性作用。
Front Immunol. 2025 Aug 7;16:1621585. doi: 10.3389/fimmu.2025.1621585. eCollection 2025.
2
Targeting the nuclear orphan receptor NR4A1: a key target in lung cancer progression and therapeutic resistance.靶向核孤儿受体NR4A1:肺癌进展和治疗耐药性的关键靶点。
Front Oncol. 2025 Jul 1;15:1566598. doi: 10.3389/fonc.2025.1566598. eCollection 2025.
3
Orphan nuclear receptor transcription factors as drug targets.

本文引用的文献

1
Not-so-opposite ends of the spectrum: CD8 T cell dysfunction across chronic infection, cancer and autoimmunity.处于光谱两端的不典型情况:慢性感染、癌症和自身免疫中 CD8 T 细胞功能障碍。
Nat Immunol. 2021 Jul;22(7):809-819. doi: 10.1038/s41590-021-00949-7. Epub 2021 Jun 17.
2
NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth.NR4A1配体作为乳腺癌细胞和肿瘤生长的强效抑制剂
Cancers (Basel). 2021 May 29;13(11):2682. doi: 10.3390/cancers13112682.
3
The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer.
孤儿核受体转录因子作为药物靶点。
Transcription. 2025 Apr-Jun;16(2-3):224-260. doi: 10.1080/21541264.2025.2521766. Epub 2025 Jul 11.
4
Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy.靶向NR4A1的谱系特异性功能用于癌症免疫治疗。
Int J Mol Sci. 2025 May 30;26(11):5266. doi: 10.3390/ijms26115266.
5
Expression of Prooncogenic Nuclear Receptor 4A (NR4A)-Regulated Genes β1-Integrin and G9a Inhibited by Dual NR4A1/2 Ligands.原癌基因核受体4A(NR4A)调控基因β1整合素和G9a的表达受双NR4A1/2配体抑制。
Int J Mol Sci. 2025 Apr 21;26(8):3909. doi: 10.3390/ijms26083909.
6
Orphan Nuclear Receptor 4A1 (NR4A1) and NR4A2are Endogenous Regulators of CD71 and TheirLigands Induce Ferroptosis in Breast Cancer.孤儿核受体4A1(NR4A1)和NR4A2是CD71的内源性调节因子,其配体可诱导乳腺癌发生铁死亡。
Res Sq. 2025 Apr 21:rs.3.rs-6214709. doi: 10.21203/rs.3.rs-6214709/v1.
7
Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.孤核受体Nur77在疾病与生理学中的争议及多重作用
FASEB J. 2025 Mar 31;39(6):e70468. doi: 10.1096/fj.202402775RR.
8
Perfluorooctane Sulfonate (PFOS) and Related Compounds Induce Nuclear Receptor 4A1 (NR4A1)-Dependent Carcinogenesis.全氟辛烷磺酸(PFOS)及相关化合物可诱导核受体4A1(NR4A1)依赖性致癌作用。
Chem Res Toxicol. 2025 Apr 21;38(4):705-716. doi: 10.1021/acs.chemrestox.4c00528. Epub 2025 Mar 11.
9
Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1.双核受体4A1(NR4A1/NR4A2)配体抑制胶质母细胞瘤生长并以TWIST1为靶点。
Mol Pharmacol. 2025 Feb;107(2):100009. doi: 10.1016/j.molpha.2024.100009. Epub 2024 Dec 31.
10
Development of a Competitive Nutrient-Based T-Cell Immunotherapy Designed to Block the Adaptive Warburg Effect in Acute Myeloid Leukemia.一种旨在阻断急性髓系白血病中适应性瓦伯格效应的基于竞争性营养物质的T细胞免疫疗法的开发。
Biomedicines. 2024 Oct 3;12(10):2250. doi: 10.3390/biomedicines12102250.
孤儿核受体 4A(NR4A)在癌症中的矛盾作用。
Mol Cancer Res. 2021 Feb;19(2):180-191. doi: 10.1158/1541-7786.MCR-20-0707. Epub 2020 Oct 26.
4
'Nur'turing tumor T cell tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity.“培育肿瘤 T 细胞耐受和衰竭:核受体 Nur77 在免疫中的新功能。”
Eur J Immunol. 2020 Nov;50(11):1643-1652. doi: 10.1002/eji.202048869. Epub 2020 Oct 25.
5
High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.免疫检查点的高表达与结直肠癌中的 TIL 负荷、突变率和患者生存相关。
Int J Oncol. 2020 Jul;57(1):237-248. doi: 10.3892/ijo.2020.5062. Epub 2020 May 8.
6
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.免疫疗法在错配修复缺陷型结直肠癌中的临床研究进展。
Clin Colorectal Cancer. 2020 Jun;19(2):73-81. doi: 10.1016/j.clcc.2020.02.002. Epub 2020 Feb 10.
7
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Memory T cell, exhaustion, and tumor immunity.记忆性T细胞、耗竭与肿瘤免疫。
Immunol Med. 2020 Mar;43(1):1-9. doi: 10.1080/25785826.2019.1698261. Epub 2019 Dec 10.
9
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.纳武利尤单抗在错配修复缺陷型非结直肠癌中有效:NCI-MATCH(EAY131)研究 Z1D-A 臂亚方案的结果。
J Clin Oncol. 2020 Jan 20;38(3):214-222. doi: 10.1200/JCO.19.00818. Epub 2019 Nov 25.
10
PTPN2 regulates the generation of exhausted CD8 T cell subpopulations and restrains tumor immunity.PTPN2 调节耗竭 CD8 T 细胞亚群的产生并抑制肿瘤免疫。
Nat Immunol. 2019 Oct;20(10):1335-1347. doi: 10.1038/s41590-019-0480-4. Epub 2019 Sep 16.